STOCK TITAN

[8-K] Neuropace, Inc. Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

NeuroPace, Inc. reported that it issued a press release announcing its financial results for the fiscal quarter ended June 30, 2025. The press release is furnished as Exhibit 99.1 to this current report and is incorporated by reference into the filing. The company explicitly states that the information in Item 2.02, including the exhibit, is furnished and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act nor incorporated by reference in filings under the Securities Act except by specific reference. No financial figures or earnings metrics are included in the text of this report.

NeuroPace, Inc. ha reso noto tramite comunicato stampa i risultati finanziari del trimestre fiscale chiuso il 30 giugno 2025. Il comunicato è fornito come Allegato 99.1 al presente rapporto e viene incorporato per riferimento nella documentazione. La società precisa espressamente che le informazioni contenute nel Punto 2.02, incluso l'allegato, sono fornite e non devono essere considerate "depositate" ai fini della Sezione 18 dello Exchange Act né incorporate per riferimento nei documenti ai sensi del Securities Act, salvo specifico richiamo. Nel testo di questo rapporto non sono riportati dati finanziari né indicatori di utile.

NeuroPace, Inc. anunció mediante un comunicado de prensa sus resultados financieros correspondientes al trimestre fiscal cerrado el 30 de junio de 2025. El comunicado se adjunta como Exhibición 99.1 a este informe y se incorpora por referencia en la presentación. La compañía declara expresamente que la información contenida en el Punto 2.02, incluido el anexo, se suministra y no deberá considerarse "presentada" a los efectos de la Sección 18 del Exchange Act ni incorporarse por referencia en las presentaciones amparadas por el Securities Act, salvo que exista una referencia específica. En el texto de este informe no se incluyen cifras financieras ni métricas de resultados.

NeuroPace, Inc.는 2025년 6월 30일 종료된 회계분기 실적을 알리는 보도자료를 발표했다고 보고했습니다. 해당 보도자료는 본 보고서의 Exhibit 99.1로 제공되며 참조를 통해 서류에 포함됩니다. 회사는 항목 2.02의 정보(첨부문서 포함)가 제공되는 것이며 "파일된 것으로 간주되지 않음"을 명시하고, 이는 Exchange Act의 섹션 18 목적상 제출된 것으로 보지 않으며 특정한 참조가 있는 경우를 제외하고는 Securities Act에 따른 제출서류에 참조로 포함되지 않는다고 명확히 밝혔습니다. 본 보고서 본문에는 재무 수치나 수익 관련 지표가 포함되어 있지 않습니다.

NeuroPace, Inc. a annoncé par communiqué de presse ses résultats financiers pour le trimestre clos le 30 juin 2025. Le communiqué est fourni en tant que Pièce 99.1 au présent rapport et y est incorporé par référence. La société précise expressément que les informations figurant à l'item 2.02, y compris la pièce jointe, sont fournies et ne doivent pas être considérées comme "déposées" au sens de la Section 18 du Exchange Act, ni incorporées par référence dans des dépôts effectués en vertu du Securities Act, sauf mention expresse. Aucun chiffre financier ni indicateur de résultat n'est inclus dans le texte de ce rapport.

NeuroPace, Inc. teilte mit, dass es eine Pressemitteilung zu den Finanzergebnissen für das am 30. Juni 2025 endende Geschäftsquartal herausgegeben hat. Die Pressemitteilung ist diesem Bericht als Anlage 99.1 beigefügt und wird durch Bezugnahme in die Einreichung aufgenommen. Das Unternehmen erklärt ausdrücklich, dass die Informationen in Punkt 2.02, einschließlich der Anlage, bereitgestellt werden und nicht als "eingereicht" im Sinne von Abschnitt 18 des Exchange Act gelten und nicht durch Bezugnahme in Unterlagen nach dem Securities Act übernommen werden, es sei denn, es erfolgt ein ausdrücklicher Verweis. In diesem Bericht sind keine finanziellen Kennzahlen oder Ertragsmaße enthalten.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: The company furnished an earnings press release but provided no financial figures in the filing, limiting immediate investor assessment.

The filing notifies investors that a press release reporting results for the fiscal quarter ended June 30, 2025, has been furnished as Exhibit 99.1. Because the 8-K itself contains no financial tables or earnings metrics, there is insufficient information in this report to evaluate revenue, profit, margins, cash flow, or balance-sheet changes. The explicit statement that the material is "furnished" and not "filed" limits its automatic incorporation into other SEC filings. Investors must review the Exhibit 99.1 press release for substantive financial detail.

TL;DR: The company followed standard disclosure practice by furnishing an earnings release and clarifying it is "furnished, not filed," which has legal and incorporation implications.

The report properly attaches the press release as Exhibit 99.1 and includes the boilerplate clarification that the Item 2.02 information is furnished rather than filed, which preserves certain liability and incorporation boundaries under the securities laws. This is a routine form of disclosure; the filing contains no governance actions, executive changes, or other corporate events beyond furnishing the earnings release.

NeuroPace, Inc. ha reso noto tramite comunicato stampa i risultati finanziari del trimestre fiscale chiuso il 30 giugno 2025. Il comunicato è fornito come Allegato 99.1 al presente rapporto e viene incorporato per riferimento nella documentazione. La società precisa espressamente che le informazioni contenute nel Punto 2.02, incluso l'allegato, sono fornite e non devono essere considerate "depositate" ai fini della Sezione 18 dello Exchange Act né incorporate per riferimento nei documenti ai sensi del Securities Act, salvo specifico richiamo. Nel testo di questo rapporto non sono riportati dati finanziari né indicatori di utile.

NeuroPace, Inc. anunció mediante un comunicado de prensa sus resultados financieros correspondientes al trimestre fiscal cerrado el 30 de junio de 2025. El comunicado se adjunta como Exhibición 99.1 a este informe y se incorpora por referencia en la presentación. La compañía declara expresamente que la información contenida en el Punto 2.02, incluido el anexo, se suministra y no deberá considerarse "presentada" a los efectos de la Sección 18 del Exchange Act ni incorporarse por referencia en las presentaciones amparadas por el Securities Act, salvo que exista una referencia específica. En el texto de este informe no se incluyen cifras financieras ni métricas de resultados.

NeuroPace, Inc.는 2025년 6월 30일 종료된 회계분기 실적을 알리는 보도자료를 발표했다고 보고했습니다. 해당 보도자료는 본 보고서의 Exhibit 99.1로 제공되며 참조를 통해 서류에 포함됩니다. 회사는 항목 2.02의 정보(첨부문서 포함)가 제공되는 것이며 "파일된 것으로 간주되지 않음"을 명시하고, 이는 Exchange Act의 섹션 18 목적상 제출된 것으로 보지 않으며 특정한 참조가 있는 경우를 제외하고는 Securities Act에 따른 제출서류에 참조로 포함되지 않는다고 명확히 밝혔습니다. 본 보고서 본문에는 재무 수치나 수익 관련 지표가 포함되어 있지 않습니다.

NeuroPace, Inc. a annoncé par communiqué de presse ses résultats financiers pour le trimestre clos le 30 juin 2025. Le communiqué est fourni en tant que Pièce 99.1 au présent rapport et y est incorporé par référence. La société précise expressément que les informations figurant à l'item 2.02, y compris la pièce jointe, sont fournies et ne doivent pas être considérées comme "déposées" au sens de la Section 18 du Exchange Act, ni incorporées par référence dans des dépôts effectués en vertu du Securities Act, sauf mention expresse. Aucun chiffre financier ni indicateur de résultat n'est inclus dans le texte de ce rapport.

NeuroPace, Inc. teilte mit, dass es eine Pressemitteilung zu den Finanzergebnissen für das am 30. Juni 2025 endende Geschäftsquartal herausgegeben hat. Die Pressemitteilung ist diesem Bericht als Anlage 99.1 beigefügt und wird durch Bezugnahme in die Einreichung aufgenommen. Das Unternehmen erklärt ausdrücklich, dass die Informationen in Punkt 2.02, einschließlich der Anlage, bereitgestellt werden und nicht als "eingereicht" im Sinne von Abschnitt 18 des Exchange Act gelten und nicht durch Bezugnahme in Unterlagen nach dem Securities Act übernommen werden, es sei denn, es erfolgt ein ausdrücklicher Verweis. In diesem Bericht sind keine finanziellen Kennzahlen oder Ertragsmaße enthalten.

0001528287false00015282872025-08-122025-08-12


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 12, 2025
NEUROPACE, INC.
(Exact name of registrant as specified in its charter)

                       Delaware
(State or Other Jurisdiction
of Incorporation)
                       001-40337
(Commission File Number)
                      22-3550230
(IRS Employer
Identification No.)
         455 N. Bernardo Avenue
           Mountain View, CA
(Address of principal executive offices)
                           94043
(Zip Code)
(650) 237-2700
Registrant's telephone number, including area code

Not Applicable
(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, $0.001 par value per shareNPCEThe Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company




If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 2.02    Results of Operations and Financial Condition.

On August 12, 2025, the Company issued a press release announcing its financial results for the fiscal quarter ended June 30, 2025. A copy of the press release, dated August 12, 2025, is furnished hereto as Exhibit 99.1 and is incorporated herein by reference.

The foregoing information in this Item 2.02 (including the exhibit hereto) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

Item 9.01    Financial Statements and Exhibits.

(d)    Exhibits.

Exhibit No.Description
99.1
Press Release, dated August 12, 2025
104Cover Page Interactive Data File (embedded within the Inline XBRL document)







SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

NeuroPace, Inc.
Dated: August 12, 2025By:/s/ Patrick Williams
Patrick Williams
Chief Financial Officer



Neuropace Inc

NASDAQ:NPCE

NPCE Rankings

NPCE Latest News

NPCE Latest SEC Filings

NPCE Stock Data

291.58M
24.06M
2.75%
86.47%
2.73%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
MOUNTAIN VIEW